Presented by


Event Sponsors

McKesson McKesson

Agency partners

Intertrade Ireland Intertrade Ireland
IDA Ireland IDA Ireland

Press release

Tuesday, 24 October 2017

• Irish Biopharma industry has the potential to create 8,400 additional jobs by 2020
• Brexit ‘cliff edge’ can be avoided by investing in research, development and innovation
• Ireland to host globally renowned BioPharma Ambition conference in 2018

BioPharmaChemIreland (BPCI)- the Ibec group that represents the sector, alongside the Irish Pharmaceutical Healthcare Association (IPHA) and the National Institute for Bioprocessing Research and Training (NIBRT), have joined forces to promote the biopharmaceutical industry in Ireland as a global powerhouse, generating revenue of €66 billion per annum.

Ireland is now set to capitalize on this by hosting a major international convention, BioPharma Ambition® in 2018, to inspire and showcase innovation in the industry. The conference, which will be held on 21-22 February 2018, brings together globally renowned experts to discuss the latest research and developments for the industry, and particularly, Irelands world-leading reputation as a hub for biotech manufacturing, testing, and Research, Development and Innovation (RDI).

Speaking at the launch of the event, Matt Moran, Director of BPCI: “The island of Ireland has established itself as a place of global significance for the biopharmaceutical industry, winning much international investment, with the top ten global biopharmaceutical companies already having an international base here. It is a testament to the substance behind the Irish business model that Ireland is considered a global champion of innovation and drug development, positively impacting the healthcare needs of patients across the world. Currently, more than 28,000 people work within the industry here, but with the right investment from policy makers, we could see that figure rise to more than 36,000 by 2020. To remain the global location of choice for the development and manufacturing of biopharmaceuticals, and to help the industry navigate Brexit uncertainty, it is essential that the Government increases investment in education, research and development for our industry. An increase in spending on science, technology and innovation to 2.5% of GDP by 2020 would be an important step in the right direction.”

IPHA CEO Oliver O’Connor stressed that the underlying theme of BioPharma Ambition 2018 would be about fostering a global environment where innovation can thrive: “Our industry is rooted in innovation, the fruits of which are vividly apparent. This is especially so in the adoption of innovation in the health services. A pro-innovation environment requires vision, commitment and long term thinking by Governments and the industry. BioPharma Ambition 2018 will be an ideal platform through which this can be developed and I am looking forward to it immensely.”

Dominic Carolan, CEO of NIBRT stated: “NIBRT is delighted to host BioPharma Ambition 2018, alongside our partners BPCI and IPHA. This important international conference gives executive level insight into all aspects of biopharmaceuticals; from exciting new medicines to manufacturing innovations. We look forward to welcoming delegates from around the world to Ireland next year.”